Zydus Cadila inks Licensing pact with Gilead for remdesivir

0
2666

Zydus Cadila inks Licensing pact with Gilead for remdesivir

Zydus Cadila has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19, informed the company in a statement.

Pankaj Patel, Chairman, Zydus Cadila said, , “We are happy to collaborate with Gilead Sciences and increase the access to this life saving drug for patients suffering from COVID 19.”

As part of the non-exclusive agreement, Zydus will receive the manufacturing know-how from Gilead Sciences Inc, to manufacture the API for Remdesivir and the finished product and market it in 127 countries, including India.

In the last decade, Zydus Cadila has been partnering with Gilead Sciences to address various public healthcare challenges and improve global access to affordable need-based therapies. At this critical juncture, we join hands once again to ensure that no efforts are spared in the fight against this pandemic,” Patel said.

Earlier, in May, three other domestic pharma firms Cipla, Jubilant Life Sciences and Hetero entered into non-exclusive licensing agreements with Gilead Sciences for manufacturing and distribution of remdesivir.

For More Information Check this link In This Link You Found Full Information Thanks For Pharma Pathway

 

Zydus Cadila inks Licensing pact with Gilead for remdesivir

LEAVE A REPLY

Please enter your comment!
Please enter your name here